|
[1]
|
Huang, J.J., Lok, V., Ngai, C., et al. (2020) Worldwide Burden of Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology, 160, 744-754.
|
|
[2]
|
Park, W., Chawla, A. and O’Reilly, E.M. (2021) Pancreatic Cancer. Journal of the American Medical Association, 326, 851-862. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ho, W.J., Zheng, L., et al. (2020) The Tumor Microenvironment in Pancreatic Cancer—Clinical Challenges and Opportunities. Nature Reviews Clinical Oncology, 17, 527-540.
|
|
[4]
|
Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., et al. (2021) Targeting Hypoxic Tumor Microenvironment in Pancreatic Cancer. Journal of Hematology & Oncology, 14, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
沈敏捷, 苗乃棣, 朱东明, 等. HIF-2、Twist在胰腺癌组织中的表达及其临床意义[J]. 江苏医药, 2016, 42(6): 633-635.
|
|
[6]
|
Luo, J. (2021) KRAS Mutation in Pancreatic Cancer. Seminars in Oncology, 48, 10-18. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Buscail, L., Bournet, B. and Cordelier, P. (2020) Role of Oncogenic KRAS in the Diagnosis, Prognosis and Treatment of Pancreatic Cancer. Nature Reviews Gastroenterology & Hepatology, 17, 153-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
敖永曦, 张启洪, 伍时佐, 等. CD8+CD28-T细胞与胰腺癌患者肿瘤标记物、生存期及治疗的关系[J]. 数理医药学杂志, 2016, 29(3): 326-328.
|
|
[9]
|
张旭, 葛春林. COX-2特异性抑制剂NS-398对胰腺癌生长及肿瘤血管生成影响[J]. 中国普通外科杂志, 2016, 25(9): 1282-1290.
|
|
[10]
|
Peter Bailey, D., Nones, C.K., et al. (2016) Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer. Nature, 531, 47-52.
|
|
[11]
|
Jones, L.E., Humphreys, M.J., Campbell, F., Neoptolemos, J.P. and Boyd, M.T. (2004) Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer. Clinical Cancer Research, 10, 2832-2845. [Google Scholar] [CrossRef] [PubMed]
|